CLINICAL_TRIALS
ClinicalTrials.gov record update
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03866382
- Title field or adapter rule
- {'original_value': 'A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)', 'source_field': 'protocolSection.identificationModule.officialTitle'}
- Ingested At
- 2026-10-31T23:27:28.435570+00:00
- Published At
- 2026-10-30T00:00:00+00:00
- Record Updated At
- 2026-10-30
- Source Retrieved At
- 2026-10-31T22:18:05.512861+00:00
- Timestamp Basis
- ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
- Date limitation
- ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Bladder Adenocarcinoma", "Bladder Clear Cell Adenocarcinoma", "Bladder Mixed Adenocarcinoma", "Bladder Neuroendocrine Carcinoma", "Bladder Small Cell Neuroendocrine Carcinoma", "Bladder Squamous Cell Carcinoma", "Chromophobe Renal Cell Carcinoma", "Collecting Duct Carcinoma", "Invasive Bladder Giant Cell Urothelial Carcinoma", "Invasive Bladder Lymphoepithelioma-Like Carcinoma", "Invasive Bladder Nested Urothelial Carcinoma", "Invasive Bladder Plasmacytoid Urothelial Carcinoma", "Invasive Bladder Sarcomatoid Urothelial Carcinoma", "Invasive Bladder Urothelial Carcinoma", "Kidney Medullary Carcinoma", "Large Cell Neuroendocrine Carcinoma", "Malignant Testicular Leydig Cell Tumor", "Malignant Testicular Sertoli Cell Tumor", "Metastatic Bladder Carcinoma", "Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma", "Metastatic Bladder Giant Cell Urothelial Carcinoma", "Metastatic Bladder Large Cell Neuroendocrine Carcinoma", "Metastatic Bladder Lipid-Rich Urothelial Carcinoma", "Metastatic Bladder Micropapillary Urothelial Carcinoma", "Metastatic Bladder Plasmacytoid Urothelial Carcinoma", "Metastatic Bladder Sarcomatoid Urothelial Carcinoma", "Metastatic Bladder Small Cell Neuroendocrine Carcinoma", "Metastatic Bladder Squamous Cell Carcinoma", "Metastatic Chromophobe Renal Cell Carcinoma", "Metastatic Kidney Medullary Carcinoma", "Metastatic Malignant Genitourinary System Neoplasm", "Metastatic Papillary Renal Cell Carcinoma", "Metastatic Penile Carcinoma", "Metastatic Prostate Small Cell Neuroendocrine Carcinoma", "Metastatic Sarcomatoid Renal Cell Carcinoma", "Metastatic Urethral Carcinoma", "Papillary Renal Cell Carcinoma", "Sarcomatoid Renal Cell Carcinoma", "Stage IV Bladder Cancer AJCC v8", "Stage IV Penile Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVB Prostate Cancer AJCC v8", "Urachal Adenocarcinoma", "Urethral Clear Cell Adenocarcinoma"]- protocolSection.statusModule.lastUpdatePostDateStruct
{"date": "2026-10-30", "type": "ACTUAL"}- protocolSection.identificationModule.nctId
"NCT03866382"- protocolSection.identificationModule.officialTitle
"A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct
null
Study condition terms
Interventions recorded in this study
- {'armGroupLabels': ['Treatment (cabozantinib, nivolumab, ipilimumab)'], 'description': 'Undergo blood and urine sample collection', 'name': 'Biospecimen Collection', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (cabozantinib, nivolumab, ipilimumab)'], 'description': 'Undergo bone scan', 'name': 'Bone Scan', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (cabozantinib, nivolumab, ipilimumab)'], 'description': 'Given PO', 'name': 'Cabozantinib S-malate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (cabozantinib, nivolumab, ipilimumab)'], 'description': 'Undergo CT and/or PET/CT scan', 'name': 'Computed Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (cabozantinib, nivolumab, ipilimumab)'], 'description': 'Undergo echocardiography', 'name': 'Echocardiography Test', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (cabozantinib, nivolumab, ipilimumab)'], 'description': 'Given IV', 'name': 'Ipilimumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (cabozantinib, nivolumab, ipilimumab)'], 'description': 'Undergo MRI', 'name': 'Magnetic Resonance Imaging', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (cabozantinib, nivolumab, ipilimumab)'], 'description': 'Given IV', 'name': 'Nivolumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
- {'armGroupLabels': ['Treatment (cabozantinib, nivolumab, ipilimumab)'], 'description': 'Undergo PET/CT scan', 'name': 'Positron Emission Tomography', 'type': 'PROCEDURE'} (protocolSection.armsInterventionsModule.interventions[])
An intervention appearing in a study record does not establish an effect or an approved use.
Drug names recorded in this source
A recorded drug name is not by itself an indication or a condition-specific relationship.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.